Jushi Holdings (JUSHF) Total Non-Current Liabilities (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Total Non-Current Liabilities of $478.4 million for Q2 2026, up 7.01% year-over-year from $447.1 million in Q2 2025, and down 3.32% quarter-over-quarter from $494.8 million in Q1 2026.
Jushi Holdings (JUSHF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Total Non-Current Liabilities for 6 consecutive years, with $478.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 7.01% year-over-year to $478.4 million; the TTM figure through Jun 2026 stood at $478.4 million (up 7.01% YoY), while the FY2025 annual figure was $471.5 million, up 11.82% from the prior year.
- Total Non-Current Liabilities fell to $478.4 million in Q2 2026 per JUSHF's latest filing, from $494.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $494.8 million in Q1 2026 and bottomed at $259.3 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $387.9 million across 5 years, with a median of $390.6 million in 2022.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 40.61% in 2023 and fell as far as 17.9% in 2023.
- Jushi Holdings' Total Non-Current Liabilities stood at $375.8 million in 2022, then retreated by 17.9% to $308.6 million in 2023, then jumped by 36.66% to $421.7 million in 2024, then increased by 11.82% to $471.5 million in 2025, then advanced by 1.47% to $478.4 million in 2026.
- Business Quant data shows JUSHF's Total Non-Current Liabilities at $478.4 million in Q2 2026, $494.8 million in Q1 2026, and $471.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | 478.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 478.44 Mn |
| Mar 31, 2026 | 494.85 Mn |
| Dec 31, 2025 | 471.50 Mn |
| Sep 30, 2025 | 423.98 Mn |
| Jun 30, 2025 | 447.08 Mn |
| Mar 31, 2025 | 438.92 Mn |
| Dec 31, 2024 | 421.66 Mn |
| Sep 30, 2024 | 411.23 Mn |
| Jun 30, 2024 | 405.29 Mn |
| Mar 31, 2024 | 317.14 Mn |
| Dec 31, 2023 | 308.55 Mn |
| Sep 30, 2023 | 364.58 Mn |
| Jun 30, 2023 | 346.39 Mn |
| Mar 31, 2023 | 368.98 Mn |
| Dec 31, 2022 | 375.82 Mn |
| Sep 30, 2022 | 259.28 Mn |
| Jun 30, 2022 | 330.09 Mn |
| Mar 31, 2022 | 318.06 Mn |
| Dec 31, 2021 | 387.14 Mn |